Catalyst
Key milestones include patient enrollment rates, safety data from the initial dose escalation, and preliminary efficacy results.
Humanexa recommends Monitor.
Date
July 18, 2026
Phase
N/A
Status
watch
Signal score
6.0
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.